SENTI BIOSCIENCES INC (SNTI)
US81726A1007 - Common Stock
SNTI Stock Earnings: Senti Biosciences Misses EPS for Q4 2023
SNTI stock results show that Senti Biosciences missed analyst estimates for earnings per share the fourth quarter of 2023.
SNTI Stock Earnings: Senti Biosciences Misses EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Senti Biosciences (NASDAQ:SNTI) just reported results for the fourth quarter of...
Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights
Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights
– IND for SENTI-202, a potential first-in-class logic-gated treatment for AML, cleared by the U.S. FDA; First patient dosing anticipated in the second...
Senti Biosciences to reduce workforce by 37% (NASDAQ:SNTI)
Senti Biosciences plans to cut workforce by ~37% to prioritize investment in its cell therapy for acute myeloid leukemia, SENTI-202.
Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program
Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program
– Strategic resource allocation to focus investment on clinical development of SENTI-202 and SENTI-301A partnership in China; interim data from Phase 1...
Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
– First patient in Phase 1 clinical trial expected to be treated in Q2 2024 – – Initial clinical efficacy data expected by year-end 2024 and durability...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Checking out the biggest pre-market stock movers for Tuesday is the perfect way to get ready for another busy day of trading!
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time to start the day with a breakdown of the biggest pre-market stock movers worth keeping an eye on for Thursday!
Senti Bio Announces Third Quarter 2023 Results and Pipeline Updates
Senti Bio Announces Third Quarter 2023 Results and Pipeline Updates
– IND for SENTI-202, a potential first-in-class logic-gated treatment for cancer, on track for clearance in Q4 2023 – – Established new strategic...
Why Is Alto Ingredients (ALTO) Stock Down 45% Today?
Alto Ingredients stock is falling on Tuesday after the company released a mixed earnings report for the third quarter of the year.
Why Is Ventyx Biosciences (VTYX) Stock Down 76% Today?
Ventyx Biosciences stock is taking a beating on Tuesday after the company announced it will end development of VTX958 on Phase 2 results.
Why Is Tharimmune (THAR) Stock Up 113% Today?
Tharimmune stock is gaining with heavy trading of THAR shares after the company announced an exclusive worldwide licensing agreement.
Why Is Senti Biosciences (SNTI) Stock Up 140% Today?
Senti Biosciences stock is rising higher on Tuesday as SNTI shares see heavy trading on a strategic collaboration announcement.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time for another dive into the biggest pre-market stock movers as we break down all of the latest news for Tuesday morning.
Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in China
Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer Annual Meeting
– Two poster presentations highlighting new preclinical data with BlueRock Therapeutics – – Two poster presentations showcasing Senti Bio’s proprietary...